AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Ex-dividend day weighs heavily on the FTSE this week
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:NWG) and Rolls-Royce Holdings PLC (LSE:RR.). There were 18.3 points collectively shaved off the index as a result of 12 blue-chips going ex-dividend on the day, when investors who purchase shares today are no longer entitled to their latest dividend payouts.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca gets clean bill of health from leading investment bank
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results. The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Iskra Reic - Executive Vice President of International Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Pascal Claude Roland Soriot - CEO & Executive Director Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Susan Mary Galbraith - Executive Vice President of Oncology R&D Conference Call Participants Gonzalo Artiach Castanon - Danske Bank A/S, Research Division James Daniel Gordon - JPMorgan Chase & Co, Research Division Luisa Caroline Hector - Joh.
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter revenue of $14.46 billion, up 12%, driven by double-digit gains in oncology and biopharmaceuticals.
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca maintains outlook as pipeline delivers strong late-stage results
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline. The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
AstraZeneca beats second-quarter profit expectations, maintains outlook
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
